Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab Deruxtecan in HER2-altered or HER2-low Advanced Solid Tumors (Real-world, China)
ChiCTR2500114397Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Jinzhou Medical University
- Start
- Dec 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of trastuzumab deruxtecan in non-small cell lung cancer (NSCLC), gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and 2 more (4 arms), sponsored by The First Affiliated Hospital of Jinzhou Medical University. Primary endpoint: Incidence of Adverse Events ≥ Grade 3. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
non-small cell lung cancer (NSCLC)gastric adenocarcinomagastroesophageal junction adenocarcinomacolorectal cancer (CRC)Nonhematologic neoplasms
Beyond the preview
Go deeper on ChiCTR2500114397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500114397.